Clinical Trial Update: Topical 0.01% Atropine for the Control of Fast Progressing Myopia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 study evaluating topical 0.01% atropine to slow fast progression of myopia in children has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Atropine (atropine)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Myopia Progressing, Childhood | Phase 2, Phase 3 | Status: TERMINATED